Safety and pharmacokinetics of PF-04360365 following a single-dose intravenous infusion in Japanese subjects with mild-to-moderate Alzheimerâ€™s disease: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study

Izuru Miyoshi; Yoko Fujimoto; Masahito Yamada; Sadahiro Abe; Qinying Zhao; Carol Cronenberger; Kanae Togo; Taro Ishibashi; Martin M. Bednar; James W. Kupiec; Brendon Binneman

doi:10.5414/cp201816

Safety and pharmacokinetics of PF-04360365 following a single-dose intravenous infusion in Japanese subjects with mild-to-moderate Alzheimerâs disease: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study

International Journal of Clinical Pharmacology and Therapeutics ◽

10.5414/cp201816 ◽

2013 ◽

Vol 51 (12) ◽

pp. 911-923 ◽

Cited By ~ 14

Author(s):

Izuru Miyoshi ◽

Yoko Fujimoto ◽

Masahito Yamada ◽

Sadahiro Abe ◽

Qinying Zhao ◽

...

Keyword(s):

Single Dose ◽

Dose Escalation ◽

Intravenous Infusion ◽

Dose Escalation Study ◽

Double Blind ◽

Double Blind Placebo ◽

Japanese Subjects

Download Full-text

Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia

Journal of Thrombosis and Haemostasis ◽

10.1111/j.1538-7836.2012.04667.x ◽

2012 ◽

Vol 10 (5) ◽

pp. 773-780 ◽

Cited By ~ 31

Author(s):

J. N. MAHLANGU ◽

M. J. COETZEE ◽

M. LAFFAN ◽

J. WINDYGA ◽

T. T. YEE ◽

...

Keyword(s):

Single Dose ◽

Phase I ◽

Dose Escalation ◽

Recombinant Factor Viia ◽

Factor Viia ◽

Dose Escalation Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Subcutaneous apomorphine in patients with advanced Parkinson's disease: A dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose

Journal of the Neurological Sciences ◽

10.1016/j.jns.2007.03.013 ◽

2007 ◽

Vol 258 (1-2) ◽

pp. 137-143 ◽

Cited By ~ 42

Author(s):

Rajesh Pahwa ◽

William C. Koller ◽

Richard M. Trosch ◽

James H. Sherry

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Single Dose ◽

Dose Escalation ◽

Dose Escalation Study ◽

Double Blind ◽

Advanced Parkinson’S Disease ◽

Double Blind Placebo ◽

Subcutaneous Apomorphine

Download Full-text

First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease

Alzheimer s & Dementia Translational Research & Clinical Interventions ◽

10.1016/j.trci.2016.06.002 ◽

2016 ◽

Vol 2 (3) ◽

pp. 169-176 ◽

Cited By ~ 20

Author(s):

James Ferrero ◽

Leslie Williams ◽

Heather Stella ◽

Kate Leitermann ◽

Alvydas Mikulskis ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Single Dose ◽

Dose Escalation ◽

Dose Escalation Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13409136.14780164 ◽

2011 ◽

Author(s):

John Laffey ◽

Mairead Hayes

Keyword(s):

Myocardial Infarction ◽

Acute Myocardial Infarction ◽

Stem Cells ◽

Mesenchymal Stem Cells ◽

Dose Escalation ◽

Human Mesenchymal Stem Cells ◽

Dose Escalation Study ◽

Double Blind ◽

Double Blind Placebo ◽

Adult Human

Download Full-text

A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of Intravenous Adult Human Mesenchymal Stem Cells (Prochymal) After Acute Myocardial Infarction

Yearbook of Cardiology ◽

10.1016/s0145-4145(10)79814-2 ◽

2010 ◽

Vol 2010 ◽

pp. 389-391 ◽

Cited By ~ 3

Author(s):

B.J. Gersh

Keyword(s):

Myocardial Infarction ◽

Acute Myocardial Infarction ◽

Stem Cells ◽

Mesenchymal Stem Cells ◽

Dose Escalation ◽

Human Mesenchymal Stem Cells ◽

Dose Escalation Study ◽

Double Blind ◽

Double Blind Placebo ◽

Adult Human

Download Full-text

First-In-Human, Double-Blind, Placebo-Controlled, Randomized, Dose-Escalation Study of BG00010, a Glial Cell Line-Derived Neurotrophic Factor Family Member, in Subjects with Unilateral Sciatica

PLoS ONE ◽

10.1371/journal.pone.0125034 ◽

2015 ◽

Vol 10 (5) ◽

pp. e0125034 ◽

Cited By ~ 16

Author(s):

Paul E. Rolan ◽

Gilmore O’Neill ◽

Eve Versage ◽

Jitesh Rana ◽

Yongqiang Tang ◽

...

Keyword(s):

Family Member ◽

Cell Line ◽

Glial Cell ◽

Dose Escalation ◽

Neurotrophic Factor ◽

Dose Escalation Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF‐06826647: A Phase I, Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Escalation Study

Clinical and Translational Science ◽

10.1111/cts.12929 ◽

2020 ◽

Cited By ~ 1

Author(s):

Ravi Shankar P. Singh ◽

Vivek Pradhan ◽

Erika S. Roberts ◽

Matthew Scaramozza ◽

Elizabeth Kieras ◽

...

Keyword(s):

Phase I ◽

Dose Escalation ◽

Dose Escalation Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Safety of the muscarinic receptor-antagonist (R,R)-penehyclidine fumarate in healthy subjects: A phase 1 randomized, double-blind, single-dose escalation study

International Journal of Clinical Pharmacology and Therapeutics ◽

10.5414/cp203535 ◽

2020 ◽

Vol 58 (03) ◽

pp. 155-165

Author(s):

Chengxiao Fu ◽

Xingfei Zhang ◽

Qi Pei ◽

Chengxian Guo ◽

Xiaoyan Yang ◽

...

Keyword(s):

Single Dose ◽

Receptor Antagonist ◽

Muscarinic Receptor ◽

Dose Escalation ◽

Healthy Subjects ◽

Phase 1 ◽

Dose Escalation Study ◽

Double Blind ◽

Muscarinic Receptor Antagonist

Download Full-text

A phase I, single-dose, double-blind, randomised, dose escalation study to assess the safety, tolerability and pharmacokinetics of NNZ-2566 when administered as a 10-minute infusion

http://isrctn.org/> ◽

10.1186/isrctn67656669 ◽

2013 ◽

Author(s):

Minh Pham

Keyword(s):

Single Dose ◽

Phase I ◽

Dose Escalation ◽

Dose Escalation Study ◽

Double Blind

Download Full-text

Safety and Immunogenicity of a Plant-Produced Recombinant Hemagglutinin-Based Influenza Vaccine (HAI-05) Derived from A/Indonesia/05/2005 (H5N1) Influenza Virus: A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study in Healthy Adults

Viruses ◽

10.3390/v4113227 ◽

2012 ◽

Vol 4 (11) ◽

pp. 3227-3244 ◽

Cited By ~ 48

Author(s):

Jessica Chichester ◽

R. Jones ◽

Brian Green ◽

Mark Stow ◽

Fudu Miao ◽

...

Keyword(s):

Influenza Virus ◽

Influenza Vaccine ◽

Dose Escalation ◽

Phase 1 ◽

H5n1 Influenza Virus ◽

Dose Escalation Study ◽

Double Blind ◽

Double Blind Placebo ◽

H5n1 Influenza ◽

Recombinant Hemagglutinin

Download Full-text

Safety and pharmacokinetics of PF-04360365 following a single-dose intravenous infusion in Japanese subjects with mild-to-moderate Alzheimerâs disease: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study

Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia

Subcutaneous apomorphine in patients with advanced Parkinson's disease: A dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose

First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease

Faculty Opinions recommendation of A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction.

A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of Intravenous Adult Human Mesenchymal Stem Cells (Prochymal) After Acute Myocardial Infarction

First-In-Human, Double-Blind, Placebo-Controlled, Randomized, Dose-Escalation Study of BG00010, a Glial Cell Line-Derived Neurotrophic Factor Family Member, in Subjects with Unilateral Sciatica

Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF‐06826647: A Phase I, Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Escalation Study

Safety of the muscarinic receptor-antagonist (R,R)-penehyclidine fumarate in healthy subjects: A phase 1 randomized, double-blind, single-dose escalation study

A phase I, single-dose, double-blind, randomised, dose escalation study to assess the safety, tolerability and pharmacokinetics of NNZ-2566 when administered as a 10-minute infusion

Safety and Immunogenicity of a Plant-Produced Recombinant Hemagglutinin-Based Influenza Vaccine (HAI-05) Derived from A/Indonesia/05/2005 (H5N1) Influenza Virus: A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study in Healthy Adults

Safety and pharmacokinetics of PF-04360365 following a single-dose intravenous infusion in Japanese subjects with mild-to-moderate Alzheimerâs disease: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study